Drug intelligence / Profile preview

177Lu-FC335

Development stage
Preclinical
Lead developer
FindCure Biosciences
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
Administration
Intravenous
01

Overview

177Lu-FC335 is a therapeutic radionuclide drug conjugate (RDC) developed by FindCure Biosciences. It consists of a peptide ligand targeting fibroblast activation protein alpha (FAPα) conjugated to the therapeutic beta-emitting radioisotope lutetium-177 (177Lu). FAPα is highly expressed in the tumor microenvironment of various solid tumors, including pancreatic, lung, esophageal, and gastric cancers, but has low expression in normal tissues. By binding to FAPα, 177Lu-FC335 delivers targeted radiation directly to the tumor stroma, inducing DNA damage and cell death in FAPα-positive solid tumors. The candidate has entered investigator-initiated trials (IIT) in China.

Other names
177Lu-labeled FC335Lu-177-FC335Lu177-FC335Lu 177-FC335
02

Targets

DNAFAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on 177Lu-FC335.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-FC335.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call